Indonesia Generic Drug Market Scope, Trends And Opportunity 2024-2032


(MENAFN- IMARC Group) IMARC Group has published a market research report titled“ Indonesia Generic Drug Market Report by Therapy Area (Central Nervous System, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Rheumatology, Diabetes, Oncology, and Others), Drug Delivery (Oral, Injectables, Dermal/Topical, Inhalers), Distribution Channel (Retail Pharmacies, Hospital Pharmacies), and Region 2024-2032 ” The Indonesia generic drug market size is projected to exhibit a growth rate (CAGR) of 8.20% during
2024-2032.

Generic drugs contain the same active ingredients, strength, dosage form, and route of administration as their brand-name counterparts. They are bioequivalent due to the production of same therapeutic effects in the body. They are cost-effective as the manufacturers do not have to invest in the research and development (R&D) activities or marketing costs associated with creating a brand-name drug. They are used in treating conditions like hypertension, diabetes, asthma, and high cholesterol. They are also utilized in acute care settings to treat acute conditions like pain, infections, allergies, and gastrointestinal issues.

Grab a sample PDF of this report: https://www.imarcgroup.com/indonesia-generic-drug-market/requestsample

Indonesia Generic Drug Market Trends and Drivers:

At present, the growing prevalence of chronic diseases, such as chronic obstructive pulmonary disease (COPD), thyroid diseases, osteoarthritis, and cardiovascular diseases, represents one of the key factors offering a favorable market outlook in Indonesia. Additionally, the increasing healthcare needs are catalyzing the demand for cost-effective alternatives to expensive brand-name medications is bolstering the growth of the market in the country. In line with this, governing agencies in Indonesia are introducing policies to promote the use of generic drugs to improve healthcare accessibility and affordability. They are also undertaking initiatives like the national health insurance program (JKN) to increase access to essential medications, which is supporting the market growth. Moreover, the rising aging population, coupled with increasing investments in expanding healthcare infrastructure, including hospitals, clinics, and pharmacies, is strengthening the growth of the market in Indonesia. Apart from this, regulatory agencies in Indonesia, such as the national agency of drug and food control (BPOM), play a crucial role in ensuring compliance with standards and fostering confidence in generic medications among healthcare professionals and patients, which is positively influencing the market. Furthermore, the increasing trend of home healthcare for several diseases that require long treatments is impelling the market growth in the country. In addition, the rising awareness among the masses about the benefits of generic drugs is offering lucrative growth opportunities to industry investors.

Report Segmentation:

The report has segmented the market into the following categories:

Therapy Area Insights:

  • Central Nervous System
  • Cardiovascular
  • Dermatology
  • Genitourinary/Hormonal
  • Respiratory
  • Rheumatology
  • Diabetes
  • Oncology
  • Others

Drug Delivery Insights:

  • Oral
  • Injectables
  • Dermal/Topical
  • Inhalers

Distribution Channel Insights:

  • Retail Pharmacies
  • Hospital Pharmacies

Regional Insights:

  • Java
  • Sumatra
  • Kalimantan
  • Sulawesi
  • Others

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email:

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163

MENAFN27022024004122016232ID1107903509


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.